(Q34730638)

4 August 2017

title

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies (English)

1 reference

4 August 2017

1 reference

1 reference

1 reference

1 reference

S Mammoliti

1

1 reference

4 August 2017

V Andretta

2

1 reference

4 August 2017

E Bennicelli

3

1 reference

4 August 2017

F Caprioni

4

1 reference

4 August 2017

D Comandini

5

1 reference

4 August 2017

G Fornarini

6

1 reference

4 August 2017

A Guglielmi

7

1 reference

4 August 2017

A Pessino

8

1 reference

4 August 2017

S Sciallero

9

1 reference

4 August 2017

A F Sobrero

10

1 reference

4 August 2017

G Mazzola

11

1 reference

4 August 2017

A Lambiase

12

1 reference

4 August 2017

C Bordignon

13

1 reference

4 August 2017

publication date

20 September 2010

1 reference

4 August 2017

1 reference

4 August 2017

volume

22

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

973-978

1 reference

Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065876

Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065876

Treatment in advanced colorectal cancer: what, when and how?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065876

Impaired angiogenesis in aminopeptidase N-null mice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065876

Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065876

Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065876

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065876

Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065876

Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065876

Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065876

There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065876

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3065876

Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells

9 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20855468

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20855468

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/ANNONC/MDQ436

1 reference

4 August 2017

1 reference

4 August 2017

1 reference